Clovis Oncology Inc - Company Profile
Powered by 
All the data and insights you need on Clovis Oncology Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Clovis Oncology Inc Strategy Report
- Understand Clovis Oncology Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Clovis Oncology Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| CA3175356A1 | Application | Immunostimulatory agents in combination with angiogenesis inhibitors | A61K2300/00; A61K31/47; A61K38/2013; A61K45/06; A61P35/00 | October 21, 2021 |
| EP3094752A4 | Search Report | Verwendung von parp-inhibitoren zur behandlung von brust- oder eierstockkrebspatientinnen mit heterozygotieverlust | A61K31/55; A61P35/00; C12Q1/68; C12Q1/6886; C12Q2600/106; C12Q2600/112; C12Q2600/156; G01N2800/60 | August 16, 2017 |
| EP3094752A1 | Application | Verwendung von parp-inhibitoren zur behandlung von brust- oder eierstockkrebspatientinnen mit heterozygotieverlust | A61K31/55; A61P35/00; C12Q1/68; C12Q1/6886; C12Q2600/106; C12Q2600/112; C12Q2600/156; G01N2800/60 | November 23, 2016 |
| CN105917007A | Application | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity | A61K31/55; A61P35/00; C12Q1/68; C12Q1/6886; C12Q2600/106; C12Q2600/112; C12Q2600/156; G01N2800/60 | August 31, 2016 |
| WO2015108986A1 | Application | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity | A61K31/55; A61P35/00; C12Q1/68; C12Q1/6886; C12Q2600/106; C12Q2600/112; C12Q2600/156; G01N2800/60 | July 23, 2015 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer